MET overexpressing chordomas frequently exhibit polysomy of chromosome 7 but no MET activation through sarcoma-specific gene fusions

Tumor Biology

Volumn 31, Issue 3, 2010, Pages 157-163

  Grabellus, Florian ^a   Konik, Margarethe J ^a   Worm, Karl ^a   Sheu, Sien Yi ^a   Van De Nes, Johannes A P ^a   Bauer, Sebastian ^a   Paulus, Werner ^b   Egensperger, Rupert ^a,c   Schmid, Kurt W ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

ASPL TFE3; Chordoma; MET protooncogene; PAX3 FKHR; SYT SSX

Indexed keywords

CELL PROTEIN; PROTEIN ASPL; PROTEIN SSX; PROTEIN SYT; PROTEIN TFE3; SCATTER FACTOR RECEPTOR; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR PAX3; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHORDOMA; CHROMOSOME 7Q; CONTROLLED STUDY; DNA PROBE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE ACTIVATION; GENE AMPLIFICATION; GENE DOSAGE; GENE FUSION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; NUMERICAL CHROMOSOME ABERRATION; POLYSOMY 7; PRIORITY JOURNAL; PROTEIN FUNCTION; PUNCH BIOPSY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARCOMA; TISSUE MICROARRAY; ADOLESCENT; ANEUPLOIDY; CHILD; CHROMOSOME 7; GENETICS; METABOLISM; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEUPLOIDY; CHILD; CHORDOMA; CHROMOSOMES, HUMAN, PAIR 7; FEMALE; GENE FUSION; HUMANS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-MET; SARCOMA; YOUNG ADULT;

EID: 77953253432     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-010-0021-0     Document Type: Article

References (42)

1. Fuchs B, Dickey ID, Yaszemski MJ, Inwards CY, Sim FH. Operative management of sacral chordoma. J Bone Joint Surg Am. 2005;87:2211-6.
2. Bergh P, Kindblom LG, Gunterberg B, Remotti F, Ryd W, Meis-Kindblom JM. Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients. Cancer. 2000;88:2122-34.
3. Weber DC, Rutz HP, Pedroni ES, Bolsi A, Timmermann B, Verwey J, et al. Results of spot-scanning proton radiation therapy for chordoma and chondrosarcoma of the skull base: the Paul Scherrer Institut experience. Int J Radiat Oncol Biol Phys. 2005;63:401-9.
4. Nguyen QN, Chang EL. Emerging role of proton beam radiation therapy for chordoma and chondrosarcoma of the skull base. Curr Oncol Rep. 2008;10:338-43.
5. Naka T, Iwamoto Y, Shinohara N, Ushijima M, Chuman H, Tsuneyoshi M. Expression of c-met proto-oncogene product (c- MET) in benign and malignant bone tumors. Mod Pathol. 1997;10:832-8.
6. Naka T, Kuester D, Boltze C, Scheil-Bertram S, Samii A, Herold C, et al. Expression of hepatocyte growth factor and c-MET in skull base chordoma. Cancer. 2008;112:104-10.
7. Weinberger PM, Yu Z, Kowalski D, Joe J, Manger P, Psyrri A, et al. Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies. Arch Otolaryngol Head Neck Surg. 2005;131:707-11.
8. Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. 2003;22:309-25.
9. Birchmeier C, Gherardi E. Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol. 1998;8:404-10.
10. Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 2005;225:1-26.
11. Benvenuti S, Comoglio PM. The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol. 2007;213:316-25.
12. Danilkovitch-Miagkova A, Zbar B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest. 2002;109:863-7.
13. Coltella N, Manara MC, Cerisano V, Trusolino L, Di Renzo MF, Scotlandi K, et al. Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma. FASEB J. 2003;17:1162-4.
14. Diomedi-Camassei F, McDowell HP, De Ioris MA, Uccini S, Altavista P, Raschella G, et al. Clinical significance of CXC chemokine receptor-4 and c-Met in childhood rhabdomyosarcoma. Clin Cancer Res. 2008;14:4119-27.
15. Rees H, Williamson D, Papanastasiou A, Jina N, Nabarro S, Shipley J, et al. The MET receptor tyrosine kinase contributes to invasive tumour growth in rhabdomyosarcomas. Growth Factors. 2006;24:197-208.
16. Wallenius V, Hisaoka M, Helou K, Levan G, Mandahl N, Meis- Kindblom JM, et al. Overexpression of the hepatocyte growth factor (HGF) receptor (Met) and presence of a truncated and activated intracellular HGF receptor fragment in locally aggressive/ malignant human musculoskeletal tumors. Am J Pathol. 2000;156:821-9.
17. Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res. 2003;63:7345-55.
18. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov. 2008;7:504-16.
19. Zhang YW, Graveel C, Shinomiya N, Vande Woude GF. Met decoys: will cancer take the bait? Cancer Cell. 2004;6:5-6.
20. Ginsberg JP, Davis RJ, Bennicelli JL, Nauta LE, Barr FG. Upregulation of MET but not neural cell adhesion molecule expression by the PAX3-FKHR fusion protein in alveolar rhabdomyosarcoma. Cancer Res. 1998;58:3542-6.
21. Tsuda M, Davis IJ, Argani P, Shukla N, McGill GG, Nagai M, et al. TFE3 fusions activate MET signaling by transcriptional upregulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res. 2007;67:919-29.
22. Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987;8:138-40.
23. Nascimento AG. World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone. Lyon: IARCPress; 2002.
24. Ma Y, Lespagnard L, Durbecq V, Paesmans M, Desmedt C, Gomez-Galdon M, et al. Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice. Clin Cancer Res. 2005;11:4393-9.
25. Wang S, Hossein SM, Frenkel EP, Haley BB, Siddiqui MT, Gokaslan S, et al. Aneusomy 17 in breast cancer: its role in HER- 2/neu protein expression and implication for clinical assessment of HER-2/neu status. Mod Pathol. 2002;15:137-45.
26. Alers JC, Krijtenburg PJ, Vissers KJ, van DH. Effect of bone decalcification procedures on DNA in situ hybridization and comparative genomic hybridization. EDTA is highly preferable to a routinely used acid decalcifier. J Histochem Cytochem. 1999;47:703-10.
27. Krishnan B, Khanna G, Clohisy D. Gene translocations in musculoskeletal neoplasms. Clin Orthop Relat Res. 2008;466:2131-46.
28. Naka T, Boltze C, Samii A, Samii M, Herold C, Ostertag H, et al. Expression of c-MET, low-molecular-weight cytokeratin, matrix metalloproteinases-1 and -2 in spinal chordoma. Histopathology. 2009;54:607-13.
29. Brandal P, Bjerkehagen B, Danielsen H, Heim S. Chromosome 7 abnormalities are common in chordomas. Cancer Genet Cytogenet. 2005;160:15-21.
30. Scheil S, Bruderlein S, Liehr T, Starke H, Herms J, Schulte M, et al. Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1. Genes Chromosomes Cancer. 2001;32:203-11.
31. Downs-Kelly E, Yoder BJ, Stoler M, Tubbs RR, Skacel M, Grogan T, et al. The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am J Surg Pathol. 2005;29:1221-7.
32. Binh MB, Sastre-Garau X, Guillou L, de Pinieux G, Terrier P, Lagace R, et al. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. Am J Surg Pathol. 2005;29:1340-7.
33. Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 1996;13:63-72.
34. Oda Y, Sakamoto A, Saito T, Kinukawa N, Iwamoto Y, Tsuneyoshi M. Expression of hepatocyte growth factor (HGF)/ scatter factor and its receptor c-MET correlates with poor prognosis in synovial sarcoma. Hum Pathol. 2000;31:185-92.
35. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res. 2009;15:2207-14.
36. Toschi L, Janne PA. Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer. Clin Cancer Res. 2008;14:5941-6.
37. Cantiani L, ManaraMC, Zucchini C,De SP, ZuntiniM, Valvassori L, et al. Caveolin-1 reduces osteosarcomametastases by inhibiting c-Src activity and met signaling. Cancer Res. 2007;67:7675-85.
38. Guo Y, Xie J, Rubin E, Tang YX, Lin F, Zi X, et al. Frzb, a secreted Wnt antagonist, decreases growth and invasiveness of fibrosarcoma cells associated with inhibition of Met signaling. Cancer Res. 2008;68:3350-60.
39. Casali PG, Messina A, Stacchiotti S, Tamborini E, Crippa F, Gronchi A, et al. Imatinib mesylate in chordoma. Cancer. 2004;101:2086-97.
40. Wachtel M, Runge T, Leuschner I, Stegmaier S, Koscielniak E, Treuner J, et al. Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry. J Clin Oncol. 2006;24:816-22.
41. Aulmann S, Longerich T, Schirmacher P, Mechtersheimer G, Penzel R. Detection of the ASPSCR1-TFE3 gene fusion in paraffin-embedded alveolar soft part sarcomas. Histopathology. 2007;50:881-6.
42. Tamborini E, Agus V, Perrone F, Papini D, Romano R, Pasini B, et al. Lack of SYT-SSX fusion transcripts in malignant peripheral nerve sheath tumors on RT-PCR analysis of 34 archival cases. Lab Invest. 2002;82:609-18.